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Abstract
Background. It is often important to extrapolate survival estimates beyond the limited follow-up 
times of clinical trials. Extrapolated survival estimates can be highly sensitive to model choice, thus 
appropriate model selection is crucial. Flexible parametric spline models have been suggested as an 
alternative to standard parametric models, however their ability to extrapolate is not well 
understood. Aim. To determine how well standard parametric and flexible parametric spline models 
predict survival when fitted to registry cohorts with artificially right-censored follow-up times. 
Methods. Adults with advanced breast, colorectal, small cell lung, non-small cell lung, or pancreatic 
cancer with a potential follow-up time of 10 years were selected from the SEER 1973-2015 registry 
dataset. Patients were classified into 15 cohorts by cancer and age group at diagnosis (18-59, 60-69, 
70+ years). Follow-up times for each cohort were right-censored at 20%, 35% and 50% survival. 
Standard parametric models (exponential, Weibull, Gompertz, log-logistic, log-normal, generalized 
gamma) and spline models (proportional hazards, proportional odds, normal/probit) were fitted to 
the 10-year dataset and the three right-censored datasets. Predicted 10-year restricted mean 
survival time and percentage surviving at 10 years were compared to the observed values. Results. 
Across all datasets the spline odds and spline normal models most frequently gave accurate 
predictions of 10-year survival outcomes. Visually, spline models tended to demonstrate better fit to 
the observed hazard functions than standard parametric models, both in the censored and 10-year 
data. Conclusions. In these cohorts, where there was little uncertainty in the observed data, the 
spline models performed well when extrapolating beyond the observed data. Spline models should 
be routinely included in the set of models that are fitted when extrapolating cancer survival data.
Key words
oncology, extrapolation, model selection, survival analysis, cost-effectiveness analysis, modelling, 
restricted mean survival time, overall survival, prediction, censoring, parametric models, flexible 
parametric spline models, Royston and Parmar spline models
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Introduction
Clinical trials for cancer pharmaceuticals, even those for metastatic cancer, are often analyzed and 
completed before all participating patients are deceased. Hence survival times for some patients are 
incomplete (right censored), mean (unrestricted) overall survival times cannot be calculated from 
observed data and extrapolation is required to estimate important differences in costs and outcomes 
between the intervention and comparator groups.1,2 Extrapolated survival estimates can be highly 
sensitive to the choice of model.3-6 Selecting an inappropriate model can strongly bias survival 
estimates and lead to inaccurate cost-effectiveness results. Thus providing adequate justification for 
the selected model increases the confidence of the decision maker in the validity of the analysis and 
hence, confidence in the results of a cost-effectiveness analysis.5,6 
Recommendations for the extrapolation of survival data5 published in 2013 state that six standard 
parametric models (exponential, Weibull, Gompertz, log-logistic, log-normal and generalized gamma) 
should be fitted to observed data and assessed for goodness of fit (e.g. using visual assessment and 
statistical measures such as the Akaike information criterion (AIC)) and for the plausibility of the 
extrapolated tail. The latter can be assessed by comparison with longer-term external data, expert 
opinion and by considering the biological plausibility of the duration of drug effects on the disease 
course.5 Whilst these recommendations were primarily focused on fitting models to RCT data, they 
are fundamentally about applying a systematic framework for model selection when extrapolating 
from incomplete survival data. Hence, they are also applicable in an observational data setting. If 
these models are found to be inappropriate, it is recommended that more flexible and complex 
modelling methods may be required, such as the flexible parametric spline models developed by 
Royston and Parmar.7 The inclusion of knots in spline models increases the models ability to fit the 
observed data, however, spline models were originally developed to model observed data with 
complex hazards, and not for the purpose of extrapolation.7 Thus there are concerns that while the 
models may improve fit to the observed data, this may not translate into improvements in the 
prediction of unobserved data.8
Recent studies have compared alternative approaches to extrapolating overall survival from clinical 
trials of immunotherapies, applying spline, cure and landmark models to reflect the proposed novel 
mechanism of action for immunotherapies. However, these studies were only able to compare 
extrapolated survival with observed survival to around three9 and five10 years, which provides a 
limited basis for assessing predictive accuracy. 
Observational data, available via cancer registries, can be used to investigate the performance of 
different extrapolation methods. While there are differences between registry and trial data (e.g. 
registries have larger cohort sizes with greater heterogeneity and different censoring patterns), the 
longer follow-up durations in registries enable extrapolated outcomes to be compared to known 
survival outcomes. The Surveillance, Epidemiology, and End Results (SEER) Program provides an 
opportunity to investigate the performance of different extrapolation methods for patients with a de 
novo diagnosis of advanced (metastatic) cancer over a long time horizon. SEER is a population-based 
registry of cancer patients managed by the National Cancer Institute (NCI) in the United States (US).11 
Large cohorts of patients with advanced breast, colorectal, non-small cell lung (NSCLC), small cell 
lung (SCLC) and pancreatic cancer are available in the SEER registry data. These cancers each have 
very different survival distributions and hazard shapes, thus providing a diverse set of case studies in 
which to investigate extrapolation methods.
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This research used the SEER data to investigate how well standard parametric models and flexible 
parametric spline models estimate observed 10-year survival outcomes (restricted mean survival 
time (RMST) and surviving percentage) when fitted to 15 different registry cohorts with follow-up 
times right-censored at 20%, 35% and 50% survival. The cohorts include large patient numbers and 
little censoring during the follow-up period, enabling the predictive accuracy of the survival models 
to be assessed when fitted to data with little uncertainty. Future analyses should build on this work 
to examine model fit with more uncertain data (with smaller sample sizes and non-uniform censoring 
throughout the observed survival period) to determine the relative importance of alternative models' 
handling of uncertainty in the data and their ability to fit the shape of the observed data.
Methods
SEER data and the patient cohorts
SEER registry data from 1973 to 2015 (the SEER9 grouping) were obtained for breast, colorectal, 
NSCLC, SCLC and pancreatic cancer patients.11,12 Patients were included in the analysis cohorts if they 
were aged 18 years or over at diagnosis and their first diagnosed tumor was advanced or metastatic 
cancer (defined as distant in the SEER historic stage A variable). Breast, colorectal and pancreatic 
cancer patients were included if diagnosed between 1973 and 2005 (enabling a minimum potential 
follow-up time of 10 years), while NSCLC and SCLC patients were included if diagnosed between 1988 
and 2005 (as the SEER historic stage A variable was not collected for these patients before 1988). All 
included breast cancer patients were female. Patients were excluded from the cohorts if they did not 
have a completed event indicator (i.e. unknown death / censoring status) or were diagnosed with the 
cancer at autopsy.
Survival times in the SEER data are reported in one month increments, with partial months rounded 
down to the last whole month. In cohorts with shorter survival times (e.g. pancreatic cancer), this 
clustering of survival times meant there were a limited number of data points (unique survival times) 
to which survival models could be fitted. To increase the number of data points and facilitate more 
robust model fitting, daily survival times were generated for each patient by randomly allocating 
them a day of the month that was added to their monthly survival time. Consistent with the SEER 
algorithm for calculating survival times, each month lasted 30.44 days (365.25/12). Patients were 
excluded from the cohorts if they had a survival time of zero days. Patients with follow-up times 
greater than 10 years were right-censored at 10 years.
There were significant differences in survival outcomes by age group at diagnosis for all five of the 
included cancers, with higher ages associated with poorer survival. This enabled each cancer cohort 
to be split into three separate age groups (18 to 59 years, 60 to 69 years, and 70 years and over) 
creating 15 analysis cohorts, each with different survival distributions and hazard shapes.
For each of the 15 cohorts, the time-point at which 20%, 35% and 50% of patients were still alive was 
identified from the Kaplan-Meier estimator. The follow-up times for all surviving patients were right-
censored at each of these time-points to generate three case study datasets for each of the 15 
cohorts (45 datasets). 
Survival models
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Six standard parametric models were fitted to each dataset, including the exponential (assumes a 
constant hazard), Weibull and Gompertz (assume a monotonically increasing or decreasing hazard), 
the log-logistic and log-normal (allow for non-monotonic hazards), and the more flexible generalized 
gamma.6,13
Flexible parametric spline models were fitted to each dataset as restricted cubic splines  where 
piecewise cubic polynomials are joined at knots while being constrained to be smooth across the 
curve and linear beyond the boundary knots.14 Spline models were fitted on three scales  
proportional hazards, proportional odds, and normal / probit. When no knots are specified these 
models are equivalent to the Weibull, log-logistic and log-normal parametric models, respectively.15 
Beyond the boundary knots where the models are constrained to be linear, the spline hazard 
behaves like a Weibull, the spline odds behaves like a log-logistic and the spline normal behaves like 
a log-normal. By default, knot locations are specified based on the number of knots chosen and the 
percentiles of uncensored event times.14 Following recommendations, the models on the three 
scales were all fitted with one to three internal knots; for each scale, the model with the lowest AIC 
was selected.7,16
Analysis
The predicted 10-year RMST and the predicted percentage of patients surviving at 10 years were 
calculated for all fitted models. To summarize the performance of each model across the 15 cohorts, 
boxplots were generated to show the median difference between predicted and observed outcomes 
(RMST and percentage surviving) at each follow-up duration, as well as the interquartile range (IQR) 
and full range. Differences were calculated as the predicted value minus the observed value. Positive 
differences indicated the model over-predicted the observed value, while negative values indicated 
the model under-predicted.
Boxplots were also generated to represent absolute differences in predictions with alternative 
follow-up times, as described for RMST for datasets with 50% and 35% of patients remaining alive: 
Absolute difference between model predictions for different follow-up durations 
= absolute (P50% ─ O) ─ absolute (P35% ─ O),
where O is the observed RMST, and P50% and P35% are the predicted RMSTs when survival has been 
right-censored at the time at which 50% and 35% of patients remain alive, respectively. Positive 
differences indicate predictions from the dataset with the longer follow-up (e.g. 35% surviving in this 
example) were more accurate.
To compare performance of the alternative fitted curves, the frequency of cases in which models 
predicted observed RMST within one month and the percentage surviving within 1% were calculated. 
These cut off points were subjectively selected to reflect decision makers interpretation of the 
accuracy of the fitted models.
To mimic the standard extrapolation approach of selecting the best fitting model, the standard 
parametric model and the spline model with the lowest AIC were selected for each of the 15 cohorts 
at each follow-up duration. Model fit for the selected parametric and spline models was compared 
using the boxplots and performance measures described above.
In order to determine whether models performed well in fitting the observed segment of the data or 
in extrapolating the unobserved tail, the 10-year RMST was calculated for each segment separately, 
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and compared for each follow-up duration using boxplots of the difference between the predicted 
and observed values.
Survival and hazard plots are provided in the supplementary materials, with example plots included 
in the paper. The observed hazard was plotted both as a smoothed hazard using kernel-based 
methods to smooth out the noise9,17, and as a piecewise exponential (PE) hazard function with three 
monthly bin widths (where the hazard has been calculated as the number of events in the bin divided 
by the total follow-up time in the bin).17 The PE hazard enables some of the underlying features of 
the data that are lost in the smoothing manipulations to be seen. The survival and hazard plots were 
examined by the authors to assess the visual fit of the models to the observed data in relation to the 
models predictions.
Software
All analyses were undertaken in R (versions 3.4.1 and 3.5.3). The flexsurv library (https://cran.r-
project.org/web/packages/flexsurv/index.html) was used to fit the standard parametric and flexible 
parametric spline models.15 Flexsurv uses maximum likelihood estimation to estimate model 
parameters. The muhaz library (https://cran.r-project.org/web/packages/muhaz) was used to 
generate the smoothed hazard (muhaz function) and the PE hazard function (pehaz function).17
Funding source
This study was funded by a grant from the National Health and Medical Research Council (NHMRC). 
Additionally, NRL was supported by the National Institute for Health Research (NIHR Post Doctoral 
Fellowship, Dr Nicholas Latimer, PDF-2015-08-022) and is now supported by Yorkshire Cancer 
Research (Award reference number S406NL). The funding agreements ensured the authors 
independence in study design, data interpretation, writing and publishing the report. The views 
expressed in this publication are those of the author(s) and not necessarily those of the NHS, the 
NIHR, the Department of Health and Social Care, or Yorkshire Cancer Research. RW chairs the 
Medical Services Advisory Committee for the Commonwealth of Australia and the views in this paper 
do not reflect those of the Commonwealth.
Results
Cohort characteristics
Table 1 presents the characteristics of the 15 cohorts. All cohorts contained large numbers of 
patients (minimum n = 5407, SCLC 18-59 years), thus sample size was not a constraint in the 
analyses. Survival distributions and hazard functions (Figure 1) varied across the cohorts, with breast 
18-59 years showing the longest survival times (10-year RMST = 42.0 months, 10-year percentage 
surviving = 14.67), and pancreatic 70 years and over showing the shortest survival times (10-year 
RMST = 3.89 months, 10-year percentage surviving = 0.21). Follow-up durations at which right-
censoring was applied (Table 1) ranged from 1.72 months (pancreatic 70+ years, 50% surviving) to 
81.43 months (breast 18-59 years, 20% surviving).
Model predictions when fitted to 10-year data
Figure 2 summarizes the differences in the accuracy of model predictions for both RMST (Figure 2a) 
and percentage surviving (Figure 2b) at 10 years and with right-censoring at the timepoints at which 
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20%, 35% and 50% of the cohort remain alive. The results are generally consistent across the two 
survival outcomes. The actual predicted values are provided in Appendix A where individual 
predictions of RMST (Figure A1, Table A1) and percentage surviving (Figure A2, Table A2) are plotted 
with 95% confidence intervals and tabled for each model, cohort and follow-up duration.
Spline models with three internal knots were most frequently selected on the basis of AIC for both 
the 10-year and right-censored datasets (Appendix B: Table B1). When fitted to the full 10-year data 
the three spline models performed better than any of the six standard parametric models (Figure 2), 
giving predictions of both RMST within one month and percentage surviving within 1% for all 15 
cohorts (Table 2). Of the standard parametric models, the Gompertz performed the best (Figure 2; 
Table 2) giving predictions of both RMST within one month and percentage surviving within 1% for 14 
of the 15 cohorts. 
Model predictions when fitted to right-censored data
Across the 15 cohorts and three right-censored follow-up durations (45 datasets) the odds scale and 
normal scale spline models gave a larger number of close predictions than any of the six standard 
parametric models (Table 2, Figure 2). For the longest follow-up times (20% survival), the log-logistic, 
log-normal, spline odds and spline normal models produced the most accurate predictions of RMST, 
but at the shorter follow-up times, the spline odds and spline normal models outperformed the other 
models. For percentage surviving at 10 years, the log-logistic, log-normal, spline odds and spline 
normal models performed similarly well over all three follow-up scenarios. When examining the 
number of cohorts in which the models produced accurate predictions of both the RMST and 
percentage surviving (Table 2), the spline normal (18/45) and spline odds (17/45) models 
outperformed the log-logistic (11/45) and log-normal models (7/45).
The exponential and Gompertz were the poorest performing models for both survival outcomes 
(Table 2, Figure 2), while the Gompertz and generalized gamma had the most variable predictions 
(Figure 2). In 11/45 datasets (Appendix A: Figure A2) the Gompertz predicted a surviving percentage 
that plateaued early and high, resulting in highly implausible predictions.
The observed surviving percentages at 10 years were very small (<2.5%) for 9 out of the 15 cohorts 
(Table 1), and some of the standard parametric models (exponential, Weibull, generalized gamma, 
and less frequently the Gompertz) tended to predict 0% surviving at 10 years for these cohorts across 
all follow-up durations. For the five cohorts in which the observed 10-year surviving percentages 
were less than 1%, these models predicted within 1% of the observed, however, their poor fit to the 
observed 10-year survival data led to poor predictions of 10-year RMST (Table 2). As an example, for 
the NSCLC 70+ years cohort censored at 50% surviving (Appendix G2) the standard parametric 
models fit well to the initial, non-censored portion of the survival curve but rapidly drop to 0% 
surviving in the extrapolated portion. This drop occurs well before survival in the long-term SEER 
data decreases to less than 1%, thus giving poor predictions of 10-year RMST.
The generalized gamma was most frequently selected as the best fitting parametric model (based 
on lowest AIC) across the three follow up durations, while the normal scale model was most 
frequently selected as the best fitting spline model (Appendix B: Table B2). The selected spline 
models (20/45) gave more accurate predictions of both RMST and percentage surviving across the 
analysis cohorts, outperforming the selected parametric models (7/45) (Figure 2, Table 2). 
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Examining the predicted RMST separately for the observed portion of the data and the extrapolated 
tail (Appendix C: Figure C1, Table C1, Table C2) suggests that both the standard parametric and spline 
models fit well to the observed portion of the data and for all models most of the difference between 
the predicted and observed 10-year RMST arises in the extrapolated tail. While the spline models 
show a small advantage over the parametric models in terms of fit to the observed portion of the 
data, particularly for longer follow-up durations (e.g. 20% surviving), they also more accurately 
extrapolate the unobserved tails. This indicates that the advantage of the spline models is not solely 
due to their enhanced fit to the observed part of the data.
Impact of longer follow-up durations on predictions
Figure 3 summarizes the differences in the accuracy of predicted survival outcomes as follow-up 
durations increase for each of the fitted models. Across the models and cohorts, longer follow-up 
times tended to improve predictions of RMST and percentage surviving at 10 years, particularly for 
the standard parametric models. Improvements were generally greater when moving from 50% 
surviving to 35% surviving, than when moving from 35% surviving to 20% surviving. 
The effect of longer follow-up times on the predictions of percentage surviving was less clear than 
the effect on RMST, predominantly due to the 9 cohorts with very small surviving percentages where 
some of the standard parametric models (exponential, Weibull, generalized gamma, and less 
frequently the Gompertz) tended to predict 0% surviving for all follow up durations. 
Assessment of hazards and model predictions
Figure 4 provides illustrative examples of model fit to the observed hazard (and survival) functions 
alongside the predicted 10-year survival outcomes. The examples were selected to illustrate the 
different hazard shapes in the observed data. Appendices C to G provide the same plots for all 15 
cohorts at all follow-up durations.
The shape of the hazard functions varied between cohorts in the first two years of follow-up, with 
three key shapes discernible. In its simplest form the hazard function decreased across the entire 10 
years of data (e.g. Figure 4c Colorectal 60-69 years and Figure 4d Breast 70+ years). For some cohorts 
the hazard showed an early increase to a peak, followed by a decrease across the remaining 10 years 
of data, i.e. a unimodal right-skewed distribution (e.g. Figure 4b NSCLC 60-69 years). The most 
complex hazard shape seen in the study cohorts was an initial decrease, followed by an increase to a 
peak before decreasing across the remaining 10 years of data (e.g. Figure 4a SCLC 18-59 years), i.e. a 
bimodal right-skewed distribution.
For all 15 cohorts the hazard showed a long-term decline, and that decline commenced at a time-
point within the first two years of follow-up. However, there were large differences in the 
percentage surviving at that time-point. Predictions tended to be less accurate for cohorts with more 
complex shapes (bimodal distributions) and shorter censoring times (where the commencement of 
the long-term decline of the hazard was not captured). 
For the SCLC 18-59 years cohort censored at 35% surviving (bimodal right-skewed hazard shape; 
Figure 4a), the complex shape and the short right-censoring time meant the data were censored 
before the hazard had commenced its long-term decline. The predicted outcomes show that the 
exponential, Weibull, spline odds and spline normal models generated the most accurate predictions. 
However, the plot of the observed and predicted hazards shows that over-time the exponential and 
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Weibull models over-predicted, under-predicted, and then over-predicted the hazard. However, 
because these balanced out, their predictions of RMST were accurate. 
The spline odds model, and the spline normal model to a lesser extent, fitted well to the observed 
hazard, despite the hazard not having peaked at the cut-off time-point. Beyond the last event in the 
censored data, the spline odds behaves like a log-logistic model, predicting a more steeply decreasing 
hazard than the spline normal model, which has the longer tail associated with a log-normal 
distribution. The log-logistic and log-normal models were unable to model the early hazard 
complexity but predicted a decreasing long-term hazard. The hazard functions for the spline hazard, 
generalized gamma, Gompertz, and Weibull models were misdirected by the increasing hazard at the 
end of the censored data and predicted increasing long-term hazards. 
For the NSCLC 60-69 years cohort censored at 35% surviving (unimodal right-skewed hazard shape; 
Figure 4b), the spline normal, spline odds, log-logistic and log-normal models produced the most 
accurate predictions of RMST. These four models tended to slightly underestimate the hazard, whilst 
the other five models mostly overestimated the observed hazard. The early peak in the observed 
hazard enabled relatively accurate predictions from the log-logistic and log-normal models, but the 
increased flexibility of the spline normal and odds models improved the fit to the peak and thus 
improved their longer-term predictions. However, it is noted that the spline normal model achieves 
the best prediction because it under- and then over-estimates the hazard (as does the log-normal)  
a feature of the longer tail associated with the log-normal model.
For the colorectal 60-69 years cohort censored at 35% surviving (simple hazard shape; Figure 4c), the 
spline odds and spline normal provided the most accurate predictions of RMST. The flexibility of 
these models enabled them to fit the flattened hazard shape observed before the censoring point, 
while still predicting declining long-term hazards similar to the observed hazard. For the breast 70+ 
years cohort censored at 35% surviving (simple hazard shape with a flat tail; Figure 4d), the Weibull 
and spline hazard models fitted very well to the observed hazard with its relatively flat decline. In 
contrast to a cohort where the percentage surviving approached zero early in the follow-up period 
(e.g. SCLC 18-59 years cohort in Figure 4a), the larger 10-year percentage surviving in this breast 
cohort (4.51%) meant that model fit in the later portion of the tail had a greater influence on the 
estimated RMST.
Discussion 
Across the 45 analyses in which the models were fitted to right-censored data, the spline odds and 
spline normal models most frequently predicted accurate estimates of longer term survival. Although 
based on large datasets with little censoring during the observed follow-up period, these findings 
may allay concerns that while spline models provide good fit to the observed data, they may be poor 
extrapolators.8 The spline models tended to better represent the early complexity of the hazard 
functions compared to the six standard parametric models. The spline odds and spline normal 
models assume shapes corresponding to log-logistic and log-normal models beyond the boundary 
knot, respectively, which tended to better represent the declining hazards in the tails of the observed 
hazard functions. 
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Examining the hazard function is a strongly recommended component of assessing model fit.6,9 In the 
analyses reported in this paper, the hazards provided a useful adjunct to the survival function, 
providing insight into the underlying shape of the observed data and the fitted models that enabled 
us to differentiate between models that appeared to fit the censored survival data equally well but 
gave very different 10-year predictions. Plotting the observed hazard as both a smoothed hazard 
function and as a PE hazard using three monthly increments provided valuable insight into both the 
overall hazard shape (smoothed) and local deviations in the hazard (PE) that influenced model fit to 
the censored data.
Across the fifteen cohorts, all observed hazards declined over the longer term and that decline 
commenced within two years of follow-up. Extrapolation may be poor in cases where the hazard is 
expected to be complex (e.g. uni- or bi-modal right-skewed hazard distributions) and the hazard in 
the right-censored data has not begun its long-term decline. In such cases follow-up should be 
continued to further elucidate the shape of the hazard and inform later additional extrapolation 
analyses. However, the spline odds and spline normal models may be used to inform an interim 
funding (or pricing) decision, as these models always assumed a decreasing hazard after the last 
event in the censored data and tended to fit to the tail of the hazard functions. The spline hazard 
model assumed a longer, flatter tail in the hazard and so may be the more appropriate choice for 
cancers in which hazards are expected to decline more slowly. The long-term decrease in hazards 
observed across all cohorts would seemingly support the use of log-logistic or log-normal survival 
models, however we found that these models predicted decreasing hazards at much earlier time 
points than the spline odds, spline normal and spline hazard models, and may lead to significant 
overestimation of RMST if the hazard is not uni-modal with an early peak. The other models failed to 
adequately reflect the declining hazard, and any accurate predictions were due to over-prediction of 
the later hazard compensating for under-prediction of the early hazard.
Model choice for data with simpler hazards (where the hazard declines throughout the follow-up 
duration) should be informed by the expected rate of decline in the long-term hazard. Even for 
simpler hazards, spline models tended performed better than parametric models as they were able 
to fit the early part of the data more accurately. Generally the spline odds and spline normal models 
provided a good fit to this shaped hazard, however the spline hazard may be the more appropriate 
model choice when a slower decline in the hazard is expected. 
The predictions of the standard parametric models were more likely than spline models to improve 
with longer follow-up durations, with the largest improvements noted for the Gompertz and 
generalized gamma models. Amongst the spline models, the spline odds generally improved with 
longer follow-up durations, but the spline normal and spline hazard were less influenced by follow-
up duration. This suggests the spline models may be more robust than the standard parametric 
models at shorter follow-up durations.
Across the fifteen cohorts, the results indicate that spline models are able to extrapolate well, at 
least in large datasets with little censoring during the observed follow-up. The results suggest that 
spline models should be included in the standard set of models that are fitted when extrapolating 
cancer survival data. The choice of spline model should be informed by prior knowledge of the 
expected shape or rate of decline of the hazard beyond the observed data, for example through the 
use of relevant external data or expert opinion. The spline hazard assumes the lowest rate of decline 
and the spline odds assumes the greatest rate of decline. The spline normal is in-between the two, 
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but tends to be closer to the spline odds than the spline hazard. The analyses of registry data 
presented in this paper provide a broad indication of long-term hazard functions for different 
advanced cancers, however the cohorts are heterogeneous. Data for more homogenous patient 
groups may be required to inform the expected long-term hazard shape for specific trial cohorts. 
Care should be taken when fitting models with a declining long-term hazard to ensure the models 
hazard does not fall below background mortality rates, particularly as hazards will increase as 
patients age.
Limitations
During the current analyses comparisons have been made between the six standard parametric 
models and the three spline models. In reality, an economic analysis would aim to select a single 
best fitting model based on model fit to the observed data and using long-term population-level 
data and clinical input to inform expectations of long-term survival.5 The authors experimented with 
options for selecting the best parametric model and best spline model for each cohort at each 
follow-up duration to enable a comparison to be made (e.g. each author independently examined 
plots showing the censored portion of the data and all fitted models extrapolated to 10 years), 
however without long-term population level data or expert clinical opinion to inform long-term 
survival there was significant variability in the models selected by different authors. To reduce the 
subjectivity of model selection, the standard parametric model and the spline model with the lowest 
AIC was selected for each cohort and used for comparison, however, the authors acknowledge there 
are important limitations associated with selecting a model for extrapolation based only on the 
assessment of model fit to the observed data.5
Advanced breast, colorectal, SCLC, NSCLC and pancreatic cancer cohorts were selected for the 
analysis due to the variation in their survival distributions and hazard shapes. Further dividing the 
cancer cohorts by age increased this variation, creating fifteen analysis cohorts and enabling model 
fit to be examined a across a diverse range of hazard shapes. The generalizability of the findings to 
other cancer cohorts will depend on the hazard shape of those cohorts, in particular whether the 
hazard is expected to decline in the long-term and the rate of that decline. 
The SEER registry cohorts used in the analysis are made up of large, highly heterogeneous 
populations with very little censoring other than that artificially introduced in the analysis. Trial 
eligibility criteria mean that enrolled patients are frequently younger, healthier, have less 
comorbidities, and are more homogenous in terms of cancer subtype than cancer patients in the 
general population.18,19 Differences between clinical trial and general patient populations will affect 
survival18,20,21, and may result in differences in the underlying hazard and the overall shape of the 
respective survival curves. The use of 15 cohorts tested the fit of the selected survival models to a 
wide range of underlying hazards and survival functions with known 10-year survival outcomes in 
which the accuracy of the extrapolation could be evaluated. In all cohorts used in the analysis the 
observed hazard declined over the long-term, however this may not be the case for other cohorts or 
cancers.
Patient numbers in clinical trials are much smaller than those seen in the SEER registry cohorts. While 
a trial may run for a defined length of time, patients are often recruited over a prolonged period, 
resulting in variable follow-up times for patients who are administratively censored at the end of the 
trial (rather than having all surviving patients censored with the exact same duration of follow-up, as 
in the registry analyses). This often results in highly uncertain tails in the survival curves, which could 
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reduce the accuracy of extrapolations. This uncertainty can be seen when the tail of the survival 
curve shifts between the interim and final datacuts of a clinical trial. Spline models are likely to follow 
the tails of the observed data more closely than the standard parametric models. Thus spline models 
may perform well when fitted to SEER registry cohorts with low levels of uncertainty, but their 
performance may be more influenced by uncertainty in the tail of trial data. Our analyses provide 
evidence that the spline models perform well under ideal conditions  where the analysis cohorts 
were large and there was little right-censoring during the observed follow-up period. Subsequent 
analyses to further test the performance of spline models could involve repeatedly taking random 
samples from registry cohorts and introducing censoring throughout the sampled time period (noting 
that registry-derived cohorts may be more heterogeneous than clinical trial populations). 
Alternatively, studies have compared extrapolations of interim datacuts of clinical trial data to the 
results of later datacuts,9,10 however, to date the duration of follow-up for the later datacuts used in 
these studies remains relatively short. Further analyses, using data with greater uncertainty, will 
enable the assessment of whether the handling of uncertainty in the data is more important than the 
ability of the model to fit the shape of the observed data.
Bias in RMST was used as the primary outcome as it is the measure of most interest to decision 
makers in health technology assessments. Model performance was summarized using the number of 
cohorts in which each model predicted within one month of the observed RMST and within 1% of the 
observed percentage surviving. Other performance measures (e.g. how frequently the observed 
value was within the predicted confidence intervals) were found to be less informative when 
comparing models in these analyses but have been included in Appendix A for thoroughness.
The presented analyses used historical registry cohorts with known survival times in order to 
compare predicted and observed survival outcomes. A 10-year time horizon was chosen for the 
extrapolation to limit the number of patients excluded because of insufficient follow up durations 
(e.g. a 20-year time horizon would have excluded patients diagnosed after 1995, while the 10-year 
time horizon excluded only those diagnosed after 2005). Other time horizon durations could have 
been chosen, and it is possible that the time horizon may affect the results, for example, prediction 
differences between models may be small at 10 years but become larger at 20 years. This is more 
likely for cohorts in which the surviving proportions are relatively large at 10 years. 
In recent clinical trials, patients with advanced cancers receiving newer cancer therapies (e.g. 
immunotherapies) have been shown to have distinctly different survival functions to similar patients 
receiving traditional chemotherapies.22 However, the presented analyses using historical registry 
data remain relevant as older chemotherapies are commonly used as the comparators for newer 
treatments. 
For immunotherapy survival data, studies have compared extrapolations from earlier datacuts to 
survival curves and outcomes observed at later datacuts.9,10 Ouwens et al9 extrapolated data with up 
to two years follow-up and compared predictions to observed survival data with up to three years 
follow-up. The fitted spline models performed as well as any other models. Bullement et al10 
compared models fitted to data with up to four years follow-up to survival observed in data with up 
to six years follow-up. Survival predictions were also compared to survival in registry data at 10 and 
15 years, with an assumption that predictions should be no worse than registry survival. This study 
reported a noticeable improvement in survival predictions for the immunotherapy arm at the later 
datacut using cure models. 
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Cure models reflect an assumption that the population of interest is comprised of groups with 
different mortality hazards, i.e. cured and non-cured patients. Cured patients are assumed to 
experience age-specific general population mortality hazards. An issue with cure models is the 
variability in the cured proportions that are fitted by different models. In the cure models fitted by 
Ouwens et al9 the cured proportions ranged from 0% to 23%, which resulted in lifetime predicted 
survival varying from 1.75 years to 5.81 years. More case studies evaluating the accuracy of 
alternative extrapolation models for patient cohorts receiving immunotherapies, with longer follow-
up, are required to confirm the advantage of cure models when extrapolating immunotherapy 
survival. Cure models are not reported in the current paper because the concept of cure is less 
relevant to historical registry cohorts, but also because there is no consensus on the application of 
cure models and the exploration of alternative approaches to the application of cure models is 
beyond the scope of this paper.
Recent analyses by Gibson et al23 suggests that spline models are able to adequately model the long-
term plateau seen in progression free survival for a proportion of immunotherapy recipients. The 
observed patterns of the longer-term hazards predicted by the spline normal, odds and hazard 
models may provide decision makers with a less complicated and adequately robust process for 
assessing longer-term survival benefits. Further improvements in the performance of spline models 
may be observed through the application of the relative survival framework that reflects the 
potential for cure by incorporating general population mortality hazards.24 
Conclusions
Fifteen large population-based cohorts of patients with de novo diagnoses of advanced breast, 
colorectal, SCLC, NSCLC and pancreatic cancer were used to evaluate predictions of long-term 
survival outcomes from six standard parametric and three flexible parametric spline models. In the 
analyzed cohorts, where there was little censoring during the observed follow-up period, the spline 
models generated the most accurate predictions across a range of hazard functions. Inspection of the 
hazard functions informed generalizable recommendations that may inform the selection of survival 
models when extrapolating cancer survival data. The three flexible parametric spline models should 
be routinely included in the set of fitted survival models when extrapolating cancer survival data. 
Replicating these analyses in clinical trial data for a variety of cancers with different survival 
distributions would provide further insight into the generalizability of the results.
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Table 1. Characteristics of the 15 cohorts
Cohort Observed 10-year outcomes
Time-points of right-censoring 
(months)
Cancer
Age group 
(years)
n
RMST 
(months)
Percentage 
surviving (%)
20% 
surviving
35% 
surviving
50% 
surviving
Breast 18-59 10480 42.00 14.67 81.43 42.00 26.03
Breast 60-69 6308 33.96 8.50 59.33 33.46 20.39
Breast 70+ 8587 26.00 4.51 44.56 23.99 12.59
Colorectal 18-59 16324 23.53 6.51 31.46 18.66 12.26
Colorectal 60-69 17378 18.59 4.01 25.07 15.13 9.53
Colorectal 70+ 32022 13.10 2.05 17.76 9.53 5.26
SCLC 18-59 5407 12.87 2.09 15.69 11.36 8.53
SCLC 60-69 7637 10.38 0.91 13.59 9.76 6.76
SCLC 70+ 8933 6.78 0.32 10.49 6.46 3.26
NSCLC 18-59 19414 13.08 2.56 15.59 9.36 6.03
NSCLC 60-69 21796 10.55 1.30 13.20 7.82 4.85
NSCLC 70+ 29257 7.88 0.50 10.23 5.76 3.43
Pancreatic 18-59 8710 8.67 1.40 9.46 5.59 3.62
Pancreatic 60-69 9888 5.65 0.43 7.00 4.30 2.72
Pancreatic 70+ 15892 3.89 0.21 4.72 2.72 1.72
RMST: restricted mean survival time. SCLC: small cell lung cancer. NSCLC: non-small cell lung cancer. 70+: 70 and over.
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Table 2. Number of cohorts in which model predictions were within 1 month of the observed restricted mean survival time (RMST) and 1% of the observed 
percentage surviving
Predictions within 1 month
of observed 10-year RMST
 Predictions within 1%
of observed 10-year percentage surviving
Predictions within both 1 month of observed RMST 
and 1% of observed percentage surviving
Right-censored at … surviving Right-censored at … surviving R 	
  t surviving
10 years
20% 35% 50%
Total
right 
censored
10 years
20% 35% 50%
Total
right 
censored
10 years
20% 35% 50%
Total
right 
censored
(Total cohorts) (15) (15) (15) (15) (45) (15) (15) (15) (15) (45) (15) (15) (15) (15) (45)
Exponential 12 2 0 1 3 5 5 5 5 15 5 1 0 0 1
Weibull 13 4 4 2 10 7 6 6 6 18 7 2 3 1 6
Gompertz 14 5 0 1 6 15 4 3 3 10 14 2 0 0 2
Log-logistic 8 7 3 2 12 10 9 8 7 24 7 6 3 2 11
Log-normal 9 7 3 1 11 10 9 6 6 21 6 4 2 1 7
Generalized gamma 14 5 3 1 9 10 6 6 4 16 10 3 3 0 6
Spline hazard 15 5 1 2 8 15 6 6 5 17 15 3 1 1 5
Spline odds 15 8 9 5 22 15 10 7 6 23 15 8 6 3 17
Spline normal 15 8 7 6 21 15 8 7 5 20 15 7 7 4 18
Selected parametric1 15 5 3 1 9 15 7 6 5 18 15 4 3 0 7
Selected spline2 15 8 7 8 23 15 8 8 6 22 15 7 8 5 20
RMST: restricted mean survival time. 1 The parametric model with the lowest AIC was selected for each cohort. 2 The spline model with the lowest AIC was selected for each cohort
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Figure caption  Figure 1
Title
Figure 1. (a)  rvv functions (b) had functions and (c) nus  isk for the 15 cohorts 
Caption
Horiaz gre ines on the surviv ot (a) show znts at which 20%, 35% and 50% of patients 
survive.
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Figure caption  Figur
Title
Figur .  redic!"ns of #$-year (%& ')!'"c! *%+ ),rviv% !"* (-./) and (0) perc+!%1 
survivin1 %cros) !2 #3 cohorts
Caption
B4ts sho5 !2 'an1 (52")6rs), inte'r,arti '%+1 (04& and *edi%+ (0%c6 "+ 5"!2in 04& of 
the differ+c 0!5en the predic!d and observed o,!c*s %c'os) !2 #3 cohorts. ) 5re 
fitted to the fu #0-year data and to the data ri1h!7cnsored at three fo57, durations. Ti*-
poin!) f' '"12!7c+)ri+1 5re based on the ti*e-point in e%c2 cohor! %! 52"c2 !2e proportion of 
patients survivin1 'eached 20%, 35% and 50%.
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Figure caption  Figur
Title
Figur8 9. :;<feren=> in the ?==@A?=C D< EDFel GA>F;=H;onI J;HK ;i=A>as;iL <DllDJo@p durations
Caption
BoxplDts shoJ HK> AanL> MJK;skers), inteAN@artil> A?iL> Mbox) and Eedi?i Mbl?=O l;i> J;HKin box) of 
the differ>i=> ;i pred;=H;ons b>HJ>>i HK> HJD =DEGar>F A;LKHo=>nsored <DllDJo@p duratioiI ?=ADII
HK> PQ =DKDrHI MM?S =DEGares 50% surviving with 35% surviving, (b) compares 35% surviving with 20% 
surviving).1 For each model in each cohort, the difference was calculated as the absolute difference 
between the predicted and observed for the shorter follow-up time minus the absolute difference 
between the predicted and observed for the longer follow-up time. 
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Figure caption  Figur
Title
FigurT U. VWXWYd shapeZ [\]^_ fit and predicted survi`W_ \dtcomes for four ^gW[h_e coj\Ykm Ynpjkq
censored at 35% surviving
Caption
Plots show the survival and hazard functions for the observed data and fitted models, and the 
difference between the 10-year predicted and 10-year observed RMST and percentage surviving for 
each model. The selected examples demonstrate model fit to (a) a complex hazard with a bimodal 
right-skewed distribution, (b) a hazard with a unimodal right-skewed distribution, (c) a simple 
declining hazard, and (d) a simple declining hazard with a flatter tail. The time-point at which the 
percentage surviving reaches 5% is indicated as predictions of the hazard are likely to have the 
greatest effect on the estimated RMST when the percentage surviving is higher i.e. before this time-
point. KM: Kaplan-Meier, PE: piecewise exponential
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Figure A1. Difference in 10−year restricted mean survival time (RMST) by model, cohort and follow−up duration
Models were fitted to each cohort with 10 years of follow−up and with the data right censored at the times 
where 20%, 35% and 50% of patients survived. Differences were calculated as predicted minus observed. 
Plot shows point estimates with 95% confidence intervals.
●
●
Model with the closest prediction for the cohort (overall)
Parametric / spline model with the closest prediction for the cohort (if not closest overall)
Difference was outside the plot range (<−10 or >10)
Gompertz plateaued early at a high percentage surviving and predictions appeared implausible
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Figure A2. Difference in percentage surviving at 10 years by model, cohort and follow−up duration
Models were fitted to each cohort with 10 years of follow−up and with the data right censored at the times 
where 20%, 35% and 50% of patients survived. Differences were calculated as predicted minus observed.
Plot shows point estimates with 95% confidence intervals.
●
●
Model with the closest prediction for the cohort (overall)
Parametric / spline model with the closest prediction for the cohort (if not closest overall)
Difference was outside the plot range (<−10 or >10)
Gompertz plateaued early at a high percentage surviving and predictions appeared implausible
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Table A1. Difference in 10-year restricted mean survival time (RMST)  by cohort, model and follow-up duration (months)
18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+
Observed RMST (months) 42.00 33.96 26.00 23.53 18.59 13.10 12.87 10.38 6.78 13.08 10.55 7.88 8.67 5.65 3.89
10 years of follow-up
Model Exponential 2.85 1.66 0.88 1.33 0.71 0.25 0.24 0.08 0.01 0.28 0.09 0.02 0.09 -0.01 0.00 12 8 2
Weibull 1.53 0.46 -0.07 1.03 0.50 -0.09 0.16 -0.02 -0.10 -0.01 -0.17 -0.23 -0.32 -0.19 -0.19 13 8 1
Gompertz 0.20 -0.43 -1.04 0.38 0.09 -0.59 0.20 -0.14 -0.05 -0.25 -0.31 -0.35 -0.58 -0.20 -0.17 14 9 1
Log-logistic 0.99 1.57 1.56 0.67 1.56 1.26 2.14 2.63 2.17 0.06 0.63 0.84 -0.09 0.64 0.43 8 2 0
Log-normal 1.30 0.82 0.62 1.32 1.53 0.82 1.75 1.64 1.11 0.30 0.42 0.39 -0.11 0.23 0.03 9 4 0
Generalized gamma 1.03 0.24 -0.24 0.85 0.56 0.19 0.18 0.05 0.05 -0.02 -0.08 -0.11 -0.28 -0.18 -0.16 14 11 0
Spline hazard 0.07 0.03 0.01 0.23 0.29 0.16 0.48 -0.13 0.02 0.10 0.07 0.00 -0.01 0.03 0.00 15 15 5
Spline odds 0.09 -0.03 -0.10 0.37 0.30 0.02 0.19 0.01 -0.15 0.13 -0.01 -0.04 0.02 -0.06 -0.04 15 15 4
Spline normal 0.10 0.03 -0.02 0.35 0.36 0.13 0.01 0.09 -0.12 0.16 0.06 -0.02 0.04 0.00 -0.02 15 15 2
Selected parametric
3 0.20 0.24 -0.24 0.38 0.09 0.19 0.20 -0.14 0.05 0.06 0.63 -0.11 -0.09 0.64 0.43 15 12 1 3
Selected spline
4 0.07 0.03 -0.02 0.23 0.29 0.02 0.01 -0.13 -0.15 0.10 -0.01 -0.04 -0.01 0.03 -0.02 15 15 6 12
5 7 7 6 7 8 7 7 7 9 9 9 9 9 9
4 7 6 4 4 5 7 7 7 7 6 5 7 6 5
Censored at 20% surviving
Model Exponential -0.69 -2.15 -2.99 -4.94 -4.02 -3.64 -2.23 -1.70 -0.94 -3.78 -2.85 -2.11 -3.07 -1.45 -1.16 2 1 0
Weibull -0.53 -0.70 -0.27 -4.65 -3.28 -2.53 -2.52 -1.44 -0.34 -3.78 -2.70 -1.87 -3.04 -1.44 -1.12 4 3 0
Gompertz -0.06 0.83 3.87 -3.12 -0.72 6.63 -3.22 -1.83 8.01 -2.91 -0.70 3.25 -2.15 -1.06 0.65 5 3 2
Log-logistic 0.78 2.62 3.47 0.17 2.05 2.15 3.01 4.08 3.78 -0.02 0.95 1.37 -0.13 0.98 0.64 7 4 3
Log-normal 1.13 2.37 3.23 0.25 1.92 1.64 2.70 3.30 2.90 -0.29 0.51 0.79 -0.61 0.44 0.09 7 3 1
Generalized gamma -0.38 -0.49 1.38 -3.76 -2.63 -0.21 -3.47 -2.49 1.38 -3.09 -1.89 -0.87 -2.56 -1.12 -0.73 5 3 1
Spline hazard -0.24 -0.55 -0.14 -3.49 -3.03 -1.79 -3.02 -2.29 -0.52 -2.94 -2.15 -1.21 -2.47 -1.19 -0.77 5 3 1
Spline odds -0.11 0.09 1.12 -1.76 -1.03 0.45 -2.03 -1.34 1.31 -1.08 -0.27 0.62 -0.85 0.07 0.32 8 4 5
Spline normal -0.15 -0.19 0.80 -2.52 -1.92 -0.56 -2.64 -1.92 0.33 -1.97 -1.22 -0.29 -1.74 -0.66 -0.34 8 3 2
Selected parametric
3 -0.06 -0.49 1.38 -3.76 -2.63 -0.21 -3.47 -2.49 1.38 -3.09 -1.89 -0.87 -2.56 -1.12 -0.73 5 3 2 2
Selected spline
4 -0.24 0.09 -0.14 -2.52 -1.92 -0.56 -2.03 -2.29 -0.52 -1.97 -1.22 -0.29 -1.74 -0.66 -0.34 8 3 4 13
8 6 3 2 1 3 0 0 4 2 4 4 3 4 7
8 6 3 2 0 1 0 0 0 2 1 0 1 1 2
Censored at 35% surviving
Model Exponential -4.96 -4.80 -5.95 -5.84 -4.70 -4.81 -1.52 -1.29 -1.27 -4.17 -3.27 -2.61 -3.36 -1.60 -1.35 0 0 0
Weibull -3.63 -0.76 -0.22 -5.84 -3.56 -3.36 -1.68 -0.31 -0.14 -4.48 -3.26 -2.47 -3.52 -1.70 -1.41 4 4 2
Gompertz -1.89 5.22 14.01 -5.48 1.98 15.73 -3.13 3.16 24.54 -4.42 -1.78 2.67 -3.46 -1.55 -1.27 0 0 0
Log-logistic 1.28 4.73 5.58 1.16 3.67 3.01 5.59 6.85 5.23 0.51 1.50 1.65 0.20 1.41 0.74 3 1 2
Log-normal 2.61 5.45 6.10 2.07 4.39 2.94 6.27 6.84 4.74 0.77 1.52 1.38 0.05 1.13 0.32 3 1 2
Generalized gamma -3.98 0.32 5.16 -5.08 -2.16 1.18 -4.10 -0.04 5.40 -3.74 -2.10 -1.12 -3.05 -1.23 -0.98 3 2 1
Spline hazard -2.52 -2.20 0.47 -5.83 -3.55 -2.01 -3.33 -2.04 2.05 -3.82 -2.53 -1.65 -3.04 -1.30 -1.13 1 1 0
Spline odds -0.72 0.64 3.99 -2.01 0.41 2.31 -1.52 0.42 6.62 -0.70 0.79 1.72 -0.59 0.82 0.40 9 5 3
Spline normal -1.16 0.09 2.82 -3.12 -1.03 0.77 -2.37 -0.72 5.01 -2.00 -0.46 0.15 -1.80 -0.31 -0.42 7 3 5
Selected parametric
3 -3.63 0.32 5.16 -5.08 -2.16 1.18 -4.10 -0.31 5.40 -3.74 -2.10 1.65 -3.05 -1.23 -0.98 3 2 0 1
Selected spline
4 -1.16 0.09 0.47 -3.12 -1.03 0.77 -2.37 -2.04 5.01 -2.00 -0.46 0.15 -1.80 -0.31 -0.42 7 4 5 14
1 4 2 0 1 1 0 4 1 3 2 1 3 2 5
1 4 2 0 1 0 0 3 1 0 0 1 3 1 0
Censored at 50% surviving
Model Exponential -6.31 -6.65 -9.42 -5.90 -5.24 -5.88 -0.55 -1.11 -2.32 -4.26 -3.58 -2.97 -3.41 -1.69 -1.41 1 0 0
Weibull -4.14 0.88 -1.48 -5.98 -3.58 -4.54 0.31 1.37 -1.63 -4.99 -3.90 -3.10 -3.78 -1.98 -1.59 2 2 2
Gompertz -2.30 17.84 28.05 -5.26 11.35 26.51 -0.73 30.52 32.14 -5.61 -3.75 -2.36 -4.09 -2.21 -1.67 1 2 0
Log-logistic 3.29 8.02 6.94 3.01 5.61 3.17 9.82 10.46 4.18 1.14 1.77 1.63 0.76 1.73 0.93 2 0 0
Log-normal 6.34 10.05 8.55 5.44 7.75 4.04 11.98 11.64 4.31 2.53 2.74 2.10 1.38 2.05 0.86 1 0 0
Generalized gamma -7.48 6.67 10.46 -4.07 0.36 2.90 -3.70 10.22 5.15 -4.34 -2.63 -1.68 -3.26 -1.52 -1.03 1 1 1
Spline hazard -3.59 0.18 3.03 -5.79 -2.58 -1.55 -3.08 0.87 1.23 -4.47 -3.06 -2.27 -3.46 -1.50 -1.03 2 2 4
Spline odds 0.43 5.24 7.60 0.17 4.00 5.92 0.34 7.23 7.68 0.12 1.48 1.94 -0.15 1.54 1.78 5 5 3
Spline normal -0.14 3.67 6.97 -1.19 2.90 3.87 -0.97 5.68 6.04 -1.42 -0.19 0.04 -1.53 0.19 0.49 6 4 5
Selected parametric
3 -7.48 6.67 10.46 -4.07 0.36 2.90 -3.70 10.22 4.31 -4.34 1.77 -1.68 -3.26 -1.52 -1.03 1 1 1 4
Selected spline
4 -0.14 0.18 6.97 -5.79 2.90 3.87 0.34 0.87 6.04 -1.42 -0.19 0.04 -1.53 0.19 0.49 8 7 7 11
2 2 0 1 1 0 5 1 0 1 1 1 2 1 3
3 2 0 1 1 0 3 1 0 1 1 1 1 1 0
Difference is calculated as predicted minus observed; 
1
 Observed value is within the predicted confidence intervals (CIs); 
2 
Comparison of the selected parametric and selected spline models only;
3
 Parametric model for each cohort selected based on lowest AIC of all parametric models; 
4
 Spline model for each cohort selected based on lowest AIC of all spline models
bold Prediction is closest to the observed value
green Gompertz plateaued early at a high percentage surviving and predictions appeared implausible
Closest 
selected 
model
2 
(count)
Breast Colorectal SCLC NSCLC Pancreatic
Within CIs
1
 (count of 9 models)
Cohort
Within 
1 month 
(count)
Within CIs
1 
(count)
Closest to 
observed 
(count)
Within 1 month (count of 9 models)
Within CIs
1
 (count of 9 models)
Within 1 month (count of 9 models)
Within CIs
1
 (count of 9 models)
Within 1 month (count of 9 models)
Within 1 month (count of 9 models)
Within CIs
1
 (count of 9 models)
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Table A2. Difference in percentage surviving at 10 years by cohort, model and follow-up duration (%)
18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+
Observed percentage surviving (%) 14.67 8.50 4.51 6.51 4.01 2.05 2.09 0.91 0.32 2.56 1.30 0.50 1.40 0.43 0.21
10 years of follow-up
Model Exponential -5.98 -4.57 -3.30 -5.67 -3.81 -2.04 -2.08 -0.91 -0.32 -2.54 -1.29 -0.50 -1.40 -0.43 -0.21 5 0 0
Weibull -2.54 -0.96 -0.25 -3.96 -2.79 -1.58 -1.99 -0.88 -0.32 -2.32 -1.23 -0.48 -1.37 -0.43 -0.21 7 1 0
Gompertz -0.06 0.27 0.73 -0.17 -0.04 0.33 -0.66 -0.18 0.16 -0.16 0.10 0.31 -0.02 0.08 0.21 15 8 4
Log-logistic 0.51 3.74 4.47 -1.23 0.29 0.95 -0.11 1.09 1.03 -0.80 0.15 0.57 -0.46 0.09 0.11 10 2 0
Log-normal 1.79 3.67 3.70 -1.21 -0.11 0.17 -0.53 0.33 0.26 -1.23 -0.40 0.02 -0.88 -0.26 -0.15 10 2 1
Generalized gamma -1.30 -0.24 0.70 -2.17 -1.59 -0.55 -1.75 -0.74 -0.25 -1.54 -0.78 -0.26 -0.99 -0.39 -0.19 10 1 0
Spline hazard -0.02 -0.05 -0.03 -0.02 -0.14 -0.23 -0.16 0.04 -0.25 -0.04 -0.11 -0.06 0.00 -0.09 -0.05 15 13 7
Spline odds -0.02 0.04 0.33 -0.24 -0.46 -0.31 -0.03 -0.20 -0.24 -0.26 -0.21 0.02 -0.10 -0.18 -0.07 15 7 1
Spline normal -0.02 0.02 0.13 -0.13 -0.31 -0.34 0.01 -0.07 -0.29 -0.14 -0.21 -0.08 -0.06 -0.17 -0.09 15 8 2
Selected parametric
3 -0.06 -0.24 0.70 -0.17 -0.04 -0.55 -0.66 -0.18 -0.25 -0.80 0.15 -0.26 -0.46 0.09 0.11 15 4 1 2
Selected spline
4 -0.02 0.02 0.13 -0.02 -0.14 -0.31 0.01 0.04 -0.24 -0.04 -0.21 0.02 0.00 -0.09 -0.09 15 11 8 13
5 6 6 4 6 7 6 8 8 5 7 9 7 9 9
5 5 4 4 3 0 4 2 0 3 2 3 4 2 1
Censored at 20% surviving
Model Exponential -8.02 -5.97 -3.95 -6.35 -3.98 -2.05 -2.09 -0.91 -0.32 -2.56 -1.30 -0.50 -1.40 -0.43 -0.21 5 0 0
Weibull -4.97 -2.06 -0.39 -6.25 -3.86 -1.99 -2.09 -0.91 -0.32 -2.56 -1.30 -0.50 -1.40 -0.43 -0.21 6 1 0
Gompertz -0.71 2.99 9.46 -4.81 -1.11 8.87 -2.09 -0.91 8.12 -2.38 -0.07 4.15 -1.13 -0.39 1.06 4 2 1
Log-logistic 0.28 4.76 6.07 -1.59 0.58 1.43 0.28 1.78 1.72 -0.85 0.28 0.78 -0.48 0.19 0.16 9 1 4
Log-normal 1.61 5.02 5.70 -1.91 0.09 0.55 -0.17 0.97 0.81 -1.46 -0.38 0.12 -1.00 -0.23 -0.14 9 2 3
Generalized gamma -3.62 -1.41 2.66 -5.71 -3.58 -0.86 -2.09 -0.91 0.04 -2.52 -1.25 -0.43 -1.40 -0.43 -0.21 6 1 1
Spline hazard -1.43 -1.78 -0.33 -5.60 -3.79 -1.83 -2.09 -0.91 -0.32 -2.53 -1.29 -0.49 -1.40 -0.43 -0.21 6 1 1
Spline odds -0.75 0.22 2.35 -3.27 -1.89 0.08 -1.92 -0.79 0.32 -1.41 -0.37 0.39 -0.77 -0.12 0.06 10 2 5
Spline normal -0.96 -0.66 1.57 -4.39 -2.92 -0.96 -2.08 -0.91 -0.21 -2.14 -1.03 -0.24 -1.27 -0.40 -0.19 8 1 0
Selected parametric
3 -0.71 -1.41 2.66 -5.71 -3.58 -0.86 -2.09 -0.91 0.04 -2.52 -1.25 -0.43 -1.40 -0.43 -0.21 7 2 1 3
Selected spline
4 -1.43 0.22 -0.33 -4.39 -2.92 -0.96 -1.92 -0.91 -0.32 -2.14 -1.03 -0.24 -1.27 -0.40 -0.19 8 2 2 11
4 2 2 0 2 4 2 8 7 1 4 8 2 9 8
2 2 2 0 1 1 1 0 1 0 1 0 0 0 0
Censored at 35% surviving
Model Exponential -10.13 -6.75 -4.26 -6.39 -3.99 -2.05 -2.09 -0.91 -0.32 -2.56 -1.30 -0.50 -1.40 -0.43 -0.21 5 0 0
Weibull -8.03 -2.12 -0.36 -6.39 -3.89 -2.02 -2.09 -0.90 -0.32 -2.56 -1.30 -0.50 -1.40 -0.43 -0.21 6 1 0
Gompertz -4.20 10.12 22.65 -6.28 1.90 18.16 -2.09 2.14 23.70 -2.56 -0.88 3.59 -1.40 -0.43 -0.21 3 0 0
Log-logistic 0.77 6.69 7.76 -0.97 1.55 1.89 1.53 3.19 2.40 -0.63 0.51 0.88 -0.37 0.31 0.19 8 0 3
Log-normal 3.04 7.74 7.96 -0.80 1.54 1.19 1.48 2.62 1.51 -1.09 -0.05 0.28 -0.86 -0.12 -0.12 6 1 3
Generalized gamma -8.64 -0.43 6.70 -6.19 -3.43 -0.11 -2.09 -0.89 1.95 -2.55 -1.27 -0.46 -1.40 -0.43 -0.21 6 2 1
Spline hazard -6.20 -4.02 0.28 -6.39 -3.89 -1.87 -2.09 -0.91 -0.12 -2.56 -1.29 -0.49 -1.40 -0.43 -0.21 6 2 2
Spline odds -2.04 1.03 5.64 -3.42 -0.91 1.33 -1.81 -0.32 3.18 -1.22 0.15 0.91 -0.68 0.12 0.09 7 2 4
Spline normal -3.15 -0.21 3.79 -4.77 -2.42 -0.21 -2.07 -0.84 1.64 -2.15 -0.80 -0.11 -1.29 -0.37 -0.19 7 2 2
Selected parametric
3 -8.03 -0.43 6.70 -6.19 -3.43 -0.11 -2.09 -0.90 1.95 -2.55 -1.27 0.88 -1.40 -0.43 -0.21 6 2 1 2
Selected spline
4 -3.15 -0.21 0.28 -4.77 -2.42 -0.21 -2.07 -0.91 1.64 -2.15 -0.80 -0.11 -1.29 -0.37 -0.19 8 3 3 13
1 2 2 2 1 2 0 6 3 1 5 8 3 9 9
0 2 2 0 0 2 0 0 1 0 2 0 0 1 0
Censored at 50% surviving
Model Exponential -10.71 -7.19 -4.44 -6.39 -4.00 -2.05 -2.08 -0.91 -0.32 -2.56 -1.30 -0.50 -1.40 -0.43 -0.21 5 0 0
Weibull -8.46 -0.83 -1.10 -6.40 -3.89 -2.04 -2.06 -0.84 -0.32 -2.56 -1.30 -0.50 -1.40 -0.43 -0.21 6 1 3
Gompertz -4.93 27.41 37.59 -6.22 12.75 28.43 -2.09 30.00 30.57 -2.56 -1.30 -0.46 -1.40 -0.43 -0.21 3 1 0
Log-logistic 2.68 9.66 8.84 0.16 2.74 1.98 3.85 5.24 1.93 -0.38 0.61 0.88 -0.19 0.41 0.23 7 1 3
Log-normal 6.64 11.92 9.95 1.40 3.70 1.75 4.80 5.37 1.34 -0.42 0.38 0.49 -0.51 0.07 -0.06 6 1 3
Generalized gamma -12.28 7.12 12.25 -5.88 -2.31 0.93 -2.09 4.14 1.84 -2.56 -1.29 -0.48 -1.40 -0.43 -0.21 4 0 1
Spline hazard -7.85 -1.64 2.70 -6.38 -3.74 -1.79 -2.09 -0.88 -0.23 -2.56 -1.30 -0.50 -1.40 -0.43 -0.21 5 1 1
Spline odds -0.78 6.18 9.30 -1.93 1.51 3.75 -1.31 2.98 3.87 -0.86 0.48 1.01 -0.53 0.34 0.50 6 1 2
Spline normal -2.07 3.79 8.13 -3.64 -0.05 1.64 -1.97 1.33 2.22 -2.01 -0.72 -0.14 -1.25 -0.32 -0.11 5 1 2
Selected parametric
3 -12.28 7.12 12.25 -5.88 -2.31 0.93 -2.09 4.14 1.34 -2.56 0.61 -0.48 -1.40 -0.43 -0.21 5 0 1 4
Selected spline
4 -2.07 -1.64 8.13 -6.38 -0.05 1.64 -1.31 -0.88 2.22 -2.01 -0.72 -0.14 -1.25 -0.32 -0.11 6 2 3 11
1 1 0 1 1 1 0 3 3 3 4 8 3 9 9
1 2 0 1 1 0 0 0 0 0 0 1 0 1 0
Difference is calculated as predicted minus observed; 
1
 Observed value is within the predicted confidence intervals (CIs); 
2 
Comparison of the selected parametric and selected spline models only;
3
 Parametric model for each cohort selected based on lowest AIC of all parametric models; 
4
 Spline model for each cohort selected based on lowest AIC of all spline models
bold Prediction is closest to the observed value
green Gompertz plateaued early at a high percentage surviving and predictions appeared implausible
Within 1 % (count of 9 models)
Within CIs
1
 (count of 9 models)
Within 1 % (count of 9 models)
Within CIs
1
 (count of 9 models)
Within 1 % (count of 9 models)
Within CIs
1
 (count of 9 models)
Within 1 % (count of 9 models)
Within CIs
1
 (count of 9 models)
Closest 
selected 
model
2 
(count)
Breast Colorectal SCLC NSCLC Pancreatic
Closest to 
observed 
(count)
Cohort
Within 1% 
(count)
Within CIs
1 
(count)
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Table B1. Number of internal knots selected for each spline model
18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 1 knot 2 knots 3 knots
10 years of follow-up Hazard 3* 3 3 3* 3* 3 2 3* 3 3* 3 3 3* 3* 3 0 1 14
Odds 3 3 3 3 3 3* 3 3 2* 3 3* 2* 3 3 2 0 3 12
Normal 3 3* 3* 3 3 3 3* 3 2 3 3 3 3 3 3* 0 1 14
Censored at 20% surviving Hazard 3* 3 3* 3 3 2 3 2* 3* 3 3 3 3 2 3 0 3 12
Odds 3 3* 3 3 3 3 3* 3 3 2 3 3 3 3 2 0 2 13
Normal 3 3 2 3* 2* 3* 3 3 3 3* 3* 3* 3* 1* 3* 1 2 12
Censored at 35% surviving Hazard 3 3 2* 2 2 3 3 3* 3 3 3 2 3 3 2 0 5 10
Odds 3 2 2 3 3 3 2 3 3 2 3 1 3 3 3 1 4 10
Normal 3* 2* 3 2* 3* 3* 2* 3 3* 1* 2* 2* 1* 3* 1* 3 5 7
Censored at 50% surviving Hazard 3 2* 2 2* 2 1 3 3* 3 2 2 3 3 3 3 1 6 8
Odds 3 2 3 3 3 1 3* 3 3 2 1 3 3 3 3 2 2 11
Normal 3* 3 3* 3 2* 3* 3 3 3* 2* 1* 1* 3* 3* 3* 2 2 11
Totals
All follow-up durations 1 knot 0 0 0 0 0 2 0 0 0 1 2 2 1 1 1 10
2 knots 0 4 4 3 4 1 3 1 2 5 2 3 0 1 3 36
3 knots 12 8 8 9 8 9 9 11 10 6 8 7 11 10 8 134
Right censored durations only 1 knot 0 0 0 0 0 2 0 0 0 1 2 2 1 1 1 10
2 knots 0 4 4 3 4 1 2 1 0 5 2 2 0 1 2 31
3 knots 9 5 5 6 5 6 7 8 9 3 5 5 8 7 6 94
* Indicates the spline model with lowest AIC overall for the cohort at that follow-up duration
Follow up duration Model scale
Totals
Breast Colorectal SCLC NSCLC Pancreatic
Cohort
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Table B2. Models selected based on lowest AIC
18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+
Selected parametric gompertz
generalized
gamma
generalized 
gamma
gompertz gompertz
generalized 
gamma
gompertz gompertz
generalized 
gamma
log-logistic log-logistic
generalized 
gamma
log-logistic log-logistic log-logistic 0 0 5 5 0 5
Selected spline
hazard, 
3 knots
normal, 
3 knots
normal, 
3 knots
hazard, 
3 knots
hazard, 
3 knots
odds, 
3 knots
normal, 
3 knots
hazard, 
3 knots
odds, 
2 knots
hazard, 
3 knots
odds, 
3 knots
odds, 
2 knots
hazard,
3 knots
hazard, 
3 knots
normal, 
3 knots
7 4 4
Selected parametric gompertz
generalized
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
0 0 1 0 0 14
Selected spline
hazard, 
3 knots
odds, 
3 knots
hazard, 
3 knots
normal, 
3 knots
normal, 
2 knots
normal, 
3 knots
odds, 
3 knots
hazard, 
2 knots
hazard, 
3 knots
normal, 
3 knots
normal, 
3 knots
normal, 
3 knots
normal, 
3 knots
normal, 
1 knots
normal, 
3 knots
4 2 9
Selected parametric weibull
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
weibull
generalized 
gamma
generalized 
gamma
generalized 
gamma
log-logistic
generalized 
gamma
generalized 
gamma
generalized 
gamma
0 2 0 1 0 12
Selected spline
normal, 
3 knots
normal, 
2 knots
hazard,
2 knots
normal, 
2 knots
normal, 
3 knots
normal, 
3 knots
normal, 
2 knots
hazard, 
3 knots
normal, 
3 knots
normal, 
1 knots
normal, 
2 knots
normal, 
2 knots
normal, 
1 knots
normal, 
3 knots
normal, 
1 knots
2 0 13
Selected parametric
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
log-normal
generalized 
gamma
log-logistic
generalized 
gamma
generalized 
gamma
generalized 
gamma
generalized 
gamma
0 0 0 1 1 13
Selected spline
normal, 
3 knots
hazard, 
2 knots
normal, 
3 knots
hazard,
2 knots
normal, 
2 knots
normal, 
3 knots
odds, 
3 knots
hazard, 
3 knots
normal, 
3 knots
normal, 
2 knots
normal, 
1 knots
normal, 
1 knots
normal, 
3 knots
normal, 
3 knots
normal, 
3 knots
3 1 11
Censored 
at 20% 
surviving
Censored 
at 35% 
surviving
Censored 
at 50% 
surviving
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Figure C1. Model predictions of restricted mean survival time (RMST) across the 15 cohorts for
(a) the observed portion of the data and (b) the extrapolated (unobserved) tail of the data
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Table C1. Difference in restricted mean survival time (RMST) for the observed portion of the data by cohort, model and follow-up duration (months)
18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+
Observed RMST at 10 years (months) 42.00 33.96 26.00 23.53 18.59 13.10 12.87 10.38 6.78 13.08 10.55 7.88 8.67 5.65 3.89
Censored at 20% surviving
Observed RMST at 20% surviving (months) 35.44 26.13 18.52 14.90 11.67 7.58 8.53 6.95 4.67 7.44 6.17 4.62 4.48 3.36 2.19
Model Exponential 1.79 1.21 1.25 0.29 0.30 0.44 -0.32 -0.08 0.20 0.12 0.15 0.17 0.09 0.04 0.06 12 1 0
Weibull 0.80 -0.01 0.02 0.18 0.06 0.12 -0.21 -0.17 0.01 0.12 0.09 0.09 0.08 0.04 0.04 15 5 0
Gompertz 0.14 -0.25 -0.45 0.03 -0.03 -0.08 -0.01 -0.05 -0.08 0.03 0.01 0.00 0.02 0.01 0.01 15 13 0
Log-logistic 0.48 -0.08 -0.29 0.03 -0.04 -0.07 -0.10 -0.17 -0.11 0.01 -0.01 -0.01 0.01 -0.01 0.00 15 13 1
Log-normal 0.28 -0.57 -0.48 -0.15 -0.21 -0.09 -0.45 -0.38 -0.13 -0.04 -0.05 -0.02 -0.02 -0.04 -0.01 15 8 0
Generalized gamma 0.53 -0.12 -0.35 0.05 -0.02 -0.05 -0.02 0.08 -0.10 0.04 0.01 0.01 0.02 0.00 0.01 15 13 0
Spline hazard 0.04 0.02 0.00 0.01 0.01 0.01 0.00 0.01 -0.01 0.01 0.00 0.00 0.00 0.00 0.00 15 15 5
Spline odds 0.05 0.01 -0.03 0.01 0.00 0.00 0.00 0.01 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 15 15 6
Spline normal 0.04 0.02 -0.04 0.01 0.01 0.00 0.01 0.01 -0.02 0.00 0.00 0.00 0.00 -0.01 0.00 15 15 3
Selected parametric
3 0.14 -0.12 -0.35 0.05 -0.02 -0.05 -0.02 0.08 -0.10 0.04 0.01 0.01 0.02 0.00 0.01 15 13 0 1
Selected spline
4 0.04 0.01 0.00 0.01 0.01 0.00 0.00 0.01 -0.01 0.00 0.00 0.00 0.00 -0.01 0.00 15 15 7 14
8 8 8 9 9 9 9 9 9 9 9 9 9 9 9
7 7 5 7 7 5 6 6 5 7 7 7 7 8 7
Censored at 35% surviving
Observed RMST at 35% surviving (months) 25.23 19.31 13.07 11.52 9.04 5.40 7.38 5.92 3.58 5.80 4.74 3.43 3.46 2.64 1.67
Model Exponential 0.43 0.76 0.94 0.02 0.18 0.27 -0.20 0.06 0.22 -0.01 0.05 0.07 0.00 0.01 0.01 15 6 1
Weibull 0.03 -0.09 0.12 0.02 0.02 0.08 -0.17 -0.07 0.08 0.04 0.05 0.05 0.02 0.02 0.02 15 9 0
Gompertz 0.01 -0.15 -0.17 0.00 -0.02 -0.02 -0.02 -0.04 -0.02 0.01 0.01 0.01 0.01 0.00 0.00 15 15 0
Log-logistic -0.11 -0.28 -0.14 -0.08 -0.08 -0.02 -0.18 -0.13 -0.01 -0.01 -0.01 0.00 -0.01 -0.01 0.00 15 13 0
Log-normal -0.52 -0.56 -0.21 -0.24 -0.19 -0.04 -0.37 -0.22 0.00 -0.08 -0.05 -0.02 -0.05 -0.03 -0.02 15 1 1
Generalized gamma 0.07 -0.19 -0.17 -0.02 -0.04 -0.02 -0.06 -0.08 -0.01 0.01 0.01 0.01 0.00 0.00 0.00 15 15 0
Spline hazard 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 15 15 7
Spline odds 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 15 15 4
Spline normal -0.01 0.00 0.00 -0.01 -0.01 0.00 0.00 -0.01 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00 15 15 2
Selected parametric
3 0.03 -0.19 -0.17 -0.02 -0.04 -0.02 -0.06 -0.07 -0.01 0.01 0.01 0.00 0.00 0.00 0.00 15 15 0 1
Selected spline
4 -0.01 0.00 0.01 -0.01 -0.01 0.00 0.00 0.00 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00 15 15 2 14
9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
7 7 7 8 7 6 5 7 7 8 6 6 8 8 7
Censored at 50% surviving
Observed RMST at 50% surviving (months) 18.58 13.85 8.31 8.83 6.68 3.61 6.18 4.64 2.23 4.41 3.50 2.46 2.64 1.98 1.25
Model Exponential 0.13 0.58 0.51 0.01 0.13 0.13 -0.02 0.15 0.08 -0.04 0.00 0.01 -0.02 -0.01 -0.01 15 8 1
Weibull -0.08 0.04 0.12 0.02 0.03 0.05 -0.08 0.03 0.04 0.01 0.02 0.02 0.01 0.01 0.01 15 10 0
Gompertz -0.01 -0.07 -0.05 0.00 -0.01 0.00 -0.02 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15 15 2
Log-logistic -0.15 -0.09 0.01 -0.04 -0.02 0.01 -0.10 -0.02 0.02 -0.01 0.00 0.00 -0.01 -0.01 0.00 15 14 0
Log-normal -0.41 -0.21 -0.03 -0.13 -0.08 0.00 -0.19 -0.05 0.01 -0.06 -0.03 -0.02 -0.04 -0.03 -0.01 15 4 0
Generalized gamma 0.01 -0.12 -0.05 -0.01 -0.02 0.00 -0.02 -0.04 0.01 0.00 0.00 0.00 0.00 0.00 0.00 15 15 1
Spline hazard 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15 15 7
Spline odds 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15 15 2
Spline normal -0.01 0.00 -0.01 -0.01 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15 15 2
Selected parametric
3 0.01 -0.12 -0.05 -0.01 -0.02 0.00 -0.02 -0.04 0.01 0.00 0.00 0.00 0.00 0.00 0.00 15 15 1 1
Selected spline
4 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15 15 5 14
9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
8 7 7 8 7 7 7 8 7 7 7 7 8 8 8
Difference is calculated as predicted minus observed; 
1
 Observed value is within the predicted confidence intervals (CIs); 
2 
Comparison of the selected parametric and selected spline models only;
3
 Parametric model for each cohort selected based on lowest AIC of all parametric models; 
4
 Spline model for each cohort selected based on lowest AIC of all spline models
bold Prediction is closest to the observed value
green Gompertz plateaued early at a high percentage surviving and predictions appeared implausible
Within 1 month (count of 9 models)
Within CIs
1
 (count of 9 models)
Within 1 month (count of 9 models)
Within CIs
1
 (count of 9 models)
Within 1 month (count of 9 models)
Within CIs
1
 (count of 9 models)
Cohort Within 
1 month 
(count)
Within CIs
1 
(count)
Closest to 
observed 
(count)
Closest 
selected 
model
2 
Breast Colorectal SCLC NSCLC Pancreatic
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Table C2. Difference in restricted mean survival time (RMST) for the extrapolated (unobserved) tail of the data by cohort, model and follow-up duration (months)
18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+ 18-59 60-69 70+
Observed RMST at 10 years (months) 42.00 33.96 26.00 23.53 18.59 13.10 12.87 10.38 6.78 13.08 10.55 7.88 8.67 5.65 3.89
Censored at 20% surviving
Observed RMST at 20% surviving (months) 6.57 7.83 7.48 8.63 6.93 5.53 4.34 3.44 2.11 5.64 4.38 3.26 4.19 2.29 1.70
Model Exponential -2.48 -3.36 -4.23 -5.23 -4.32 -4.08 -1.90 -1.62 -1.14 -3.90 -2.99 -2.29 -3.16 -1.49 -1.21 0 0 1
Weibull -1.33 -0.69 -0.28 -4.82 -3.34 -2.64 -2.31 -1.27 -0.35 -3.90 -2.79 -1.97 -3.12 -1.49 -1.17 3 1 2
Gompertz -0.19 1.08 4.31 -3.16 -0.69 6.71 -3.21 -1.78 8.09 -2.94 -0.71 3.25 -2.17 -1.07 0.65 4 1 1
Log-logistic 0.29 2.70 3.76 0.14 2.08 2.22 3.12 4.24 3.89 -0.03 0.96 1.38 -0.14 0.99 0.63 7 3 3
Log-normal 0.85 2.94 3.71 0.40 2.13 1.73 3.16 3.68 3.03 -0.25 0.56 0.81 -0.59 0.48 0.10 8 0 1
Generalized gamma -0.91 -0.37 1.73 -3.81 -2.61 -0.15 -3.46 -2.57 1.49 -3.12 -1.90 -0.88 -2.58 -1.12 -0.74 5 1 1
Spline hazard -0.29 -0.58 -0.14 -3.51 -3.04 -1.80 -3.02 -2.29 -0.51 -2.94 -2.15 -1.21 -2.47 -1.19 -0.77 5 2 1
Spline odds -0.16 0.09 1.15 -1.77 -1.03 0.46 -2.03 -1.35 1.33 -1.09 -0.27 0.62 -0.86 0.08 0.31 8 2 4
Spline normal -0.19 -0.21 0.85 -2.53 -1.93 -0.56 -2.64 -1.93 0.35 -1.97 -1.22 -0.29 -1.74 -0.65 -0.34 8 2 1
Selected parametric
3 -0.19 -0.37 1.73 -3.81 -2.61 -0.15 -3.46 -2.57 1.49 -3.12 -1.90 -0.88 -2.58 -1.12 -0.74 5 2 1 2
Selected spline
4 -0.29 0.09 -0.14 -2.53 -1.93 -0.56 -2.03 -2.29 -0.51 -1.97 -1.22 -0.29 -1.74 -0.65 -0.34 8 3 3 13
7 5 3 2 1 3 0 0 3 2 4 4 3 4 7
5 3 2 1 0 0 0 0 0 1 0 0 0 0 0
Censored at 35% surviving
Observed RMST at 35% surviving (months) 16.77 14.65 12.93 12.01 9.55 7.70 5.50 4.46 3.20 7.28 5.81 4.45 5.21 3.01 2.23
Model Exponential -5.39 -5.56 -6.89 -5.86 -4.88 -5.07 -1.32 -1.35 -1.49 -4.16 -3.32 -2.68 -3.36 -1.61 -1.35 0 0 1
Weibull -3.66 -0.67 -0.35 -5.86 -3.58 -3.44 -1.51 -0.23 -0.23 -4.52 -3.31 -2.52 -3.54 -1.72 -1.42 4 0 2
Gompertz -1.89 5.37 14.18 -5.48 2.00 15.75 -3.11 3.20 24.56 -4.43 -1.79 2.66 -3.47 -1.55 -1.27 0 0 0
Log-logistic 1.39 5.01 5.72 1.25 3.74 3.03 5.77 6.98 5.24 0.52 1.51 1.65 0.21 1.41 0.74 3 0 2
Log-normal 3.13 6.01 6.31 2.31 4.58 2.98 6.65 7.06 4.74 0.85 1.57 1.40 0.10 1.16 0.34 3 0 2
Generalized gamma -4.04 0.51 5.34 -5.06 -2.13 1.20 -4.04 0.04 5.41 -3.74 -2.10 -1.13 -3.05 -1.23 -0.98 3 1 1
Spline hazard -2.51 -2.21 0.46 -5.83 -3.55 -2.01 -3.33 -2.04 2.06 -3.83 -2.52 -1.65 -3.04 -1.30 -1.13 1 0 0
Spline odds -0.71 0.64 4.00 -2.01 0.41 2.31 -1.52 0.43 6.63 -0.70 0.79 1.72 -0.60 0.82 0.40 9 0 2
Spline normal -1.15 0.09 2.82 -3.12 -1.03 0.77 -2.37 -0.71 5.02 -1.99 -0.45 0.15 -1.80 -0.31 -0.42 7 1 5
Selected parametric
3 -3.66 0.51 5.34 -5.06 -2.13 1.20 -4.04 -0.23 5.41 -3.74 -2.10 1.65 -3.05 -1.23 -0.98 3 0 0 1
Selected spline
4 -1.15 0.09 0.46 -3.12 -1.03 0.77 -2.37 -2.04 5.02 -1.99 -0.45 0.15 -1.80 -0.31 -0.42 7 1 5 14
1 4 2 0 1 1 0 4 1 3 2 1 3 2 5
0 1 0 0 0 0 0 1 0 0 0 0 0 0 0
Censored at 50% surviving
Observed RMST at 50% surviving (months) 23.42 20.11 17.69 14.70 11.91 9.49 6.70 5.74 4.54 8.67 7.06 5.42 6.03 3.67 2.64
Model Exponential -6.44 -7.22 -9.93 -5.91 -5.37 -6.01 -0.52 -1.26 -2.40 -4.22 -3.58 -2.98 -3.39 -1.67 -1.40 1 0 0
Weibull -4.07 0.84 -1.60 -5.99 -3.62 -4.59 0.39 1.34 -1.67 -5.00 -3.92 -3.12 -3.79 -1.98 -1.60 2 0 1
Gompertz -2.29 17.92 28.10 -5.26 11.35 26.51 -0.71 30.53 32.13 -5.62 -3.75 -2.36 -4.09 -2.22 -1.67 1 0 0
Log-logistic 3.43 8.11 6.93 3.05 5.63 3.16 9.93 10.49 4.16 1.15 1.77 1.63 0.77 1.73 0.93 2 0 0
Log-normal 6.76 10.26 8.58 5.57 7.83 4.05 12.18 11.69 4.30 2.59 2.77 2.12 1.42 2.08 0.87 1 0 0
Generalized gamma -7.49 6.79 10.50 -4.05 0.38 2.90 -3.69 10.26 5.14 -4.34 -2.63 -1.68 -3.26 -1.52 -1.02 1 0 1
Spline hazard -3.59 0.18 3.03 -5.78 -2.58 -1.55 -3.08 0.88 1.23 -4.47 -3.06 -2.27 -3.46 -1.50 -1.02 2 1 4
Spline odds 0.44 5.25 7.60 0.17 4.00 5.92 0.33 7.24 7.67 0.12 1.48 1.94 -0.15 1.54 1.78 5 0 4
Spline normal -0.14 3.66 6.97 -1.18 2.90 3.87 -0.97 5.68 6.04 -1.42 -0.19 0.04 -1.53 0.19 0.49 6 1 5
Selected parametric
3 -7.49 6.79 10.50 -4.05 0.38 2.90 -3.69 10.26 4.30 -4.34 1.77 -1.68 -3.26 -1.52 -1.02 1 0 1 4
Selected spline
4 -0.14 0.18 6.97 -5.78 2.90 3.87 0.33 0.88 6.04 -1.42 -0.19 0.04 -1.53 0.19 0.49 8 2 8 11
2 2 0 1 1 0 5 1 0 1 1 1 2 1 3
1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
Difference is calculated as predicted minus observed; 
1
 Observed value is within the predicted confidence intervals (CIs); 
2 
Comparison of the selected parametric and selected spline models only;
3
 Parametric model for each cohort selected based on lowest AIC of all parametric models; 
4
 Spline model for each cohort selected based on lowest AIC of all spline models
bold Prediction is closest to the observed value
green Gompertz plateaued early at a high percentage surviving and predictions appeared implausible
Within 1 month (count of 9 models)
Within CIs
1
 (count of 9 models)
Within 1 month (count of 9 models)
Within CIs
1
 (count of 9 models)
Within 1 month (count of 9 models)
Within CIs
1
 (count of 9 models)
Cohort Within 
1 month 
(count)
Within CIs
1 
(count)
Closest 
selected 
model
2 
Breast Colorectal SCLC NSCLC Pancreatic
Closest to 
observed 
(count)
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Figure D1. Breast 18−59 years cohort 
(All models)
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(e) 10−year observed outcomes
RMST = 42.00 months; percentage surviving = 14.67%
Figure D2. Breast 60−69 years cohort 
(All models)
(a) Survival (%)
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(c) Predicted outcomes
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(e) 10−year observed outcomes
RMST = 33.96 months; percentage surviving = 8.50%
Figure D3. Breast 70+ years cohort 
(All models)
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(c) Predicted outcomes
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(e) 10−year observed outcomes
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Figure E1. Colorectal 18−59 years cohort 
(All models)
(a) Survival (%)
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(e) 10−year observed outcomes
RMST = 23.53 months; percentage surviving = 6.50%
Figure E2. Colorectal 60−69 years cohort 
(All models)
(a) Survival (%)
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(e) 10−year observed outcomes
RMST = 18.59 months; percentage surviving = 4.01%
Figure E3. Colorectal 70+ years cohort 
(All models)
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Figure F1. SCLC 18−59 years cohort 
(All models)
(a) Survival (%)
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(e) 10−year observed outcomes
RMST = 12.87 months; percentage surviving = 2.09%
Figure F2. SCLC 60−69 years cohort 
(All models)
(a) Survival (%)
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(e) 10−year observed outcomes
RMST = 10.38 months; percentage surviving = 0.91%
Figure F3. SCLC 70+ years cohort 
(All models)
(a) Survival (%)
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Figure G1. NSCLC 18−59 years cohort 
(All models)
(a) Survival (%)
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(e) 10−year observed outcomes
RMST = 13.08 months; percentage surviving = 2.56%
Figure G2. NSCLC 60−69 years cohort 
(All models)
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(e) 10−year observed outcomes
RMST = 10.55 months; percentage surviving = 1.30%
Figure G3. NSCLC 70+ years cohort 
(All models)
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(e) 10−year observed outcomes
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Figure H1. Pancreatic 18−59 years cohort 
(All models)
(a) Survival (%)
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(e) 10−year observed outcomes
RMST = 8.67 months; percentage surviving = 1.40%
Figure H2. Pancreatic 60−69 years cohort 
(All models)
(a) Survival (%)
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(e) 10−year observed outcomes
RMST = 5.65 months; percentage surviving = 0.43%
Figure H3. Pancreatic 70+ years cohort 
(All models)
(a) Survival (%)
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(e) 10−year observed outcomes
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